Janssen Vaccine Less Effective Against Delta Variant
According to the preliminary results of a study published Tuesday, the vaccine from Janssen (Johnson & Johnson) is much less effective against the Delta variant than against the original coronavirus, about which The New York Times reports.
According to the study, the Janssen vaccine, for which only one shot is used, produces relatively few antibodies against the Delta variant, which has not yet been published in a scientific journal. In addition, researchers at New York University concluded that the drug produces about five times fewer protective antibodies against this mutant than against the unmutated lung virus.
“We don’t want to discourage people from taking the Janssen vaccine, but we do hope that in the future it will be possible to get a second shot, from Janssen itself or from Pfizer or Moderna,” says virologist Nathaniel Landau of the University of Amsterdam. New York, who led the study, told The New York Times.
According to the study, the vaccines from Pfizer and Moderna also produced relatively fewer antibodies against the Delta variant, but this difference would be smaller.
The American health authorities reported on Tuesday that 83 percent of new corona cases in the United States now involve the more contagious Delta variant. At the beginning of the month, it was still about 50 percent.